Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Novartis AG (NOVN.SW)

Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
76.32-0.61 (-0.79%)
At close: 5:31PM CEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close76.93
Open76.83
Bid0.00 x 0
Ask0.00 x 0
Day's Range75.96 - 76.99
52 Week Range70.42 - 86.92
Volume2,197,289
Avg. Volume3,365,856
Market Cap170.708B
Beta (5Y Monthly)0.55
PE Ratio (TTM)20.92
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield3.00 (3.90%)
Ex-Dividend DateMar 04, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for NOVN.SW

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    All
    News
    • GlobeNewswire

      Sandoz completes acquisition of GSK’s cephalosporin business, reinforcing leading global position in antibiotics

      Sandoz gains rights to three established brands sold in more than 100 marketsTransaction, including leading global brand Zinnat®, complements Sandoz leadership in generic penicillins with leading position in cephalosporinsAcquisition confirms Sandoz commitment to antibiotics, following announcement of further investment plans for European-based manufacturing network Basel, October 11, 2021 – Sandoz, a Novartis division, has successfully completed the acquisition of GSK’s cephalosporin antibiotic

    • GlobeNewswire

      Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs

      Company previously disclosed settlement agreement in principle and fully provisioned for this resolution Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has entered a settlement agreement with the Civil Division of the U.S. Department of Justice (DOJ) concerning the Department’s years-long pricing investigation into the U.S. generic drug industry. This settlement is an expected outcome of the resolution the company reached in March 2020 with the DOJ Antitrust Division regard

    • GlobeNewswire

      Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions

      Reached nearly 29 million patients to date in 2021 through our flagship programs and strategic innovative brandsAnnounced a planned 10-year commitment with historically black colleges and universities to address root causes of systemic disparities in health outcomesContinued our global health leadership with positive phase 2b results for our next generation antimalarial therapy ganaplacide in combination with lumefantrine which support its continued developmentCommitted to achieving net zero car

    Advertisement
    Advertisement